{'fraction_non_alphanumeric': 0.04506363949088407, 'fraction_numerical': 0.007223942208462332, 'mean_word_length': 5.778554778554779, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Increasing Rates of Diagnosis, Substantial Co-occurrence, and Variable Treatment Patterns of Eosinophilic Gastritis, Gastroenteritis and Colitis Based on 10 Year Data Across a Multi-Center Consortium

Financial Support and Acknowledgements Support for this project was provided through a research training grant as part of the Consortium of Eosinophilic Gastrointestinal Disease Researchers (CEGIR) (U54 AI117804). CEGIR is part of the Rare Disease Clinical Research Network (RDCRN), an initiative of the Office of Rare Diseases Research (ORDR), NCATS, and is funded through collaboration between NIAID, NIDDK, and NCATS. CEGIR is also supported by patient advocacy groups including APFED CURED and EFC. This project also received support from NIH T32 DK007634 (CCR). Author Disclosers Patricia Fulkerson: Grant funding from the NIH; Consultant for Genentech, Inc; Research support from Knopp Biosciences, LLC. Gary Falk: Research support from Shire, Celgene, Adare, Regeneron. Consulting for Shire Jonathan M. Spergel: Consultant for Regeneron, DBV Technology, Kaleo; Grant funding from DBV Technology, Aimmune Therapeutics, Food Allergy Research Education; Royalties from UpToDate Nirmala Gonsalves: Royalties from UpToDate; Advisory board for Allakos Sandeep K Gupta: Consultant for Alkalos, Abbott, QOL, Receptos; research support from Shire Glenn Furuta: Founder of EnteroTrack; Consultant for Shire; Royalties from UpToDate Marc E. Rothenberg: Consultant for Pulm One, Spoon Guru, ClostraBio, Celgene, Shire, Astra Zeneca, GlaxoSmithKline, Allakos, Adare, Regeneron and Novartis and has an equity interest in the first four listed and Immune Pharmaceuticals, and royalties from reslizumab (Teva Pharmaceuticals), PEESSv2 (Mapi Research Trust) and UpToDate. M.E.R. is an inventor of patents owned by Cincinnati Children’s. Evan Dellon: Consultant for Adare, Allakos, Alivio, Banner, Celgen/Receptos, Enumeral, GSK, Regeneron, Shire; Research funding from Adare, Celegene/Receptos, Miraca, Meritage, Nutricia, Regeneron, Shire, Educational grant from Banner, Holoclara Study Highlights What is current knowledge? Eosinophilic gastrointestinal disorders (EGIDs) include eosinophilic esophagitis (EoE), eosinophilic gastritis (EG), gastroenteritis (EGE), and colitis (EC). Non-EoE EGIDs are rare with most studies limited to case reports or review of single center experiences. There are no widely established guidelines for the diagnosis of EG, EGE, or EC. What is new here? In this multicenter study, EG, EGE, and EC were all diagnosed with increasing frequency over the past decade. Presenting symptoms are non-specific and do not reliably distinguish between disorders. There was no male predominance and the majority of subjects had atopy. Co-occurrence of EG, EGE, and EC diagnoses is common, seen in 41% of patients. There is substantial variability between centers in initial treatment approaches.